In the specification:

Please amend paragraph [0011] as follows:

[0011] For example, the pharmaceutical dosage forms of the present invention may include an immediate release component and said controlled release component wherein each comprises an AAAD inhibitor and levodopa in a ratio of from about 1:1 to about 1:50; wherein the immediate release component exhibits an in vitro dissolution profile comprising at least about 10% levodopa release after 15 minutes and at least about 60% levodopa release after about 1 hour; and wherein the controlled release component exhibits an in vitro dissolution profile comprising from about 10% to about 60% levodopa release after 1 hour ~~minutes~~, from about 20% to about 80% levodopa release after 2 hours, and at least about 30% levodopa release after 6 hours. The pharmaceutical dosage forms of the present invention may also exhibit an *in vivo* plasma profile comprising a levodopa release peak from about 6 minutes to about 6 hours after administration to a fasting patient. Furthermore, the pharmaceutical dosage forms of the present invention may include a COMT inhibitor in the immediate release component, the controlled release component, or both.

Please amend paragraph [0029] as follows:

[0029] AAAD inhibitors known in the art include carbidopa, benserazide, alpha-monofluoromethyldopa, and 3-hydroxybenzylhydrazine. Carbidopa is a known AAAD inhibitor having the formula (-)-L-(α-hydrazino-(α-methyl-β-(3-4-dihydroxybenzene) propanoic acid monohydrate. Levodopa is a known aromatic amino acid precursor of dopamine having the formula (-)-L-α-amino-β-(3-4-dihydroxybenzene) propanoic acid. COMT inhibitors include CGP-28014, entacapone, and tolcapone.